CKMSynced Forum

Embracing a holistic approach to DKD, CVD and CKM comorbidities with empagliflozin

NEPHROLOGY CARDIOLOGY DIABETES & ENDOCRINOLOGY
04 Jul 2025

The cardiovascular, kidney, and metabolic (CKM) systems are interconnected through complex and multifactorial interaction and neurohormonal feedback mechanisms. In this webinar, Dr. Janaka Karalliedde from the Guy’s and St Thomas’ Hospital, King’s College London, the United Kingdom, highlights the significance of recognizing and addressing all three conditions, type 2 diabetes mellitus (T2D), diabetic kidney disease (DKD) and heart failure (HF), as well as the impact of empagliflozin on renal outcomes, cardiovascular benefits and mortality risks.

Dr. Karalliedde further emphasized the need for early intervention and the role of primary care physicians in screening and treating patients early with sodium-glucose cotransporter 2 inhibitors (SGLT2is) such as empagliflozin to maximize the potential benefits of the drug on the CKM systems and patients’ quality of life.

 

Get access to our exclusive articles.
Related Articles

Empagliflozin as an efficacious novel oral option for youth-onset type 2 diabetes patients without insulin therapy: Post-hoc analysis of the DINAMO trial

STUDY DESIGN Compared to their adult counterparts, children and adolescents with type 2 diabetes mellitus (T2DM) experience an accelerated deterioration in beta-cell function and development of insulin resistance, thereby elevating their risk of early-onset complications. Currently, treatment optio
DIABETES & ENDOCRINOLOGY
29 Dec 2023

Understanding the mechanism of benefits of dapagliflozin in HFpEF: An invasive hemodynamic randomized trial

Heart failure with preserved ejection fraction (HFpEF) constitutes >50% of all heart failure (HF) cases, with few effective treatments.1It is known that elevation in left heart filling pressures at rest and during exercise are the pathophysiologic features of HFpEF, andthat sodium-glucose co-transporter-2 inhibitors (SGLT2is), such as dapagliflozin and empagliflozin, have been shown to reduce therisk of HF and cardiovascular (CV) death, while improving the quality of life (QoL) in patients with HFpEF.1 However, the mechanismsbehind this are still unclear.1
CARDIOLOGY
11 May 2023

Empagliflozin achieves clinically meaningful reduction in HbA1c among young T2D patients

A recent phase 3 clinical trial demonstrated that empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, achieved a statistically significant reduction in glycated hemoglobin (HbA1c) when compared with placebo among children aged 10-17 years with type 2 diabetes (T2D) who had previously
DIABETES & ENDOCRINOLOGY
30 Jan 2023